The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors - Fig 3

<p><b>Algorithm for identifying CHC patients receiving TVR (A) and BOC (B) with an increased likelihood to achieve SVR by combining pre-treatment and on-treatment factors.</b></p

Treatment efficacy of the cohort receiving TVR, BOC or both PIs.

<p>Treatment efficacy of the cohort receiving TVR, BOC or both PIs.</p

Baseline factors and their association with cirrhosis status in the study cohort.

<p>Baseline factors and their association with cirrhosis status in the study cohort.</p

Baseline characteristics of the PI-treated cohorts and the association of pre-treatment factors with SVR.

<p>Baseline characteristics of the PI-treated cohorts and the association of pre-treatment factors with SVR.</p

Associations of HCV RNA and antigen measurements with SVR in TVR treatment.

<p>Associations of HCV RNA and antigen measurements with SVR in TVR treatment.</p

The most significant predictors of TVR therapy-induced SVR in CHC and their corresponding predictive values.

<p>The most significant predictors of TVR therapy-induced SVR in CHC and their corresponding predictive values.</p

A snapshot of an interactive map plotting the prevalence of transmitted drug resistance in 111 countries from 287 studies between 2000 and 2013 (http://hivdb.stanford.edu/surveillance/map/).

<p>Each study is represented by a circle. The size of the circle is proportional to the number of individuals in the study. The circle color indicates the prevalence of overall TDR in the study: white (<2.5%), pale yellow (2.5% to 4.9%), orange (5.0% to 9.9%), and red (≥10.0%). Each study can also be located on a sidebar, which lists each publication, percent overall TDR, number of individuals, and the country (or countries) where the study was conducted. Clicking on a sidebar row or a study circle in the interactive version of the map at <a href="http://hivdb.stanford.edu/surveillance/map/" target="_blank">http://hivdb.stanford.edu/surveillance/map/</a> generates a pop-up box with additional information including a link to the appropriate PubMed reference, the TDR prevalence by ARV class, the median year of virus sampling, the source of virus isolation, the mechanism of participant recruitment, and the virus subtype distribution (a pop-up box of the study Bila13 is shown as an example). The complete set of data associated with a study can be reviewed by clicking on the “Resistance (%)” link either on the sidebar or within the study circle pop-up menu.</p

Flow chart showing the derivation of study sets meeting meta-analysis inclusion criteria: studies of representative ARV-naïve populations of 25 or more individuals with published RT sequences with or without protease sequences.

<p>Flow chart showing the derivation of study sets meeting meta-analysis inclusion criteria: studies of representative ARV-naïve populations of 25 or more individuals with published RT sequences with or without protease sequences.</p